These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 17498953)
1. A new class of histamine H3 receptor antagonists derived from ligand based design. Roche O; Rodríguez Sarmiento RM Bioorg Med Chem Lett; 2007 Jul; 17(13):3670-5. PubMed ID: 17498953 [TBL] [Abstract][Full Text] [Related]
3. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore. Axe FU; Bembenek SD; Szalma S J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444 [TBL] [Abstract][Full Text] [Related]
4. Selective naphthalene H(3) receptor inverse agonists with reduced potential to induce phospholipidosis and their quinoline analogs. Rodríguez Sarmiento RM; Nettekoven MH; Taylor S; Plancher JM; Richter H; Roche O Bioorg Med Chem Lett; 2009 Aug; 19(15):4495-500. PubMed ID: 19524437 [TBL] [Abstract][Full Text] [Related]
5. Development of a selective and potent radioactive ligand for histamine H(3) receptors: A compound potentially useful for receptor occupancy studies. Mitobe Y; Ito S; Mizutani T; Nagase T; Sato N; Tokita S Bioorg Med Chem Lett; 2009 Aug; 19(15):4075-8. PubMed ID: 19553110 [TBL] [Abstract][Full Text] [Related]
6. An investigation of the absolute configuration of the potent histamine H3 receptor antagonist GT-2331 using vibrational circular dichroism. Minick DJ; Copley RC; Szewczyk JR; Rutkowske RD; Miller LA Chirality; 2007 Sep; 19(9):731-40. PubMed ID: 17575572 [TBL] [Abstract][Full Text] [Related]
7. Molecular modeling of histamine H3 receptor and QSAR studies on arylbenzofuran derived H3 antagonists. Dastmalchi S; Hamzeh-Mivehroud M; Ghafourian T; Hamzeiy H J Mol Graph Model; 2008 Jan; 26(5):834-44. PubMed ID: 17561422 [TBL] [Abstract][Full Text] [Related]
8. Model of a specific human histamine H3 receptor (hH3R) binding pocket suitable for virtual drug design. Schlegel B; Stark H; Sippl W; Höltje HD Inflamm Res; 2005 Apr; 54 Suppl 1():S50-1. PubMed ID: 15928832 [No Abstract] [Full Text] [Related]
9. Refinement of histamine H3 ligands pharmacophore model leads to a new class of potent and selective naphthalene inverse agonists. Roche O; Nettekoven M; Vifian W; Sarmiento RM Bioorg Med Chem Lett; 2008 Aug; 18(15):4377-9. PubMed ID: 18606542 [TBL] [Abstract][Full Text] [Related]
10. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists. Hancock AA Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092 [TBL] [Abstract][Full Text] [Related]
11. Non-imidazole histamine H3 ligands. Part III. New 4-n-propylpiperazines as non-imidazole histamine H3-antagonists. Walczyński K; Zuiderveld OP; Timmerman H Eur J Med Chem; 2005 Jan; 40(1):15-23. PubMed ID: 15642406 [TBL] [Abstract][Full Text] [Related]
12. Validation of a histamine H3 receptor model through structure-activity relationships for classical H3 antagonists. Lorenzi S; Mor M; Bordi F; Rivara S; Rivara M; Morini G; Bertoni S; Ballabeni V; Barocelli E; Plazzi PV Bioorg Med Chem; 2005 Oct; 13(19):5647-57. PubMed ID: 16085419 [TBL] [Abstract][Full Text] [Related]
13. Novel imidazole-based histamine H3 antagonists. Jablonowski JA; Ly KS; Bogenstaetter M; Dvorak CA; Boggs JD; Dvorak LK; Lord B; Miller KL; Mazur C; Wilson SJ; Lovenberg TW; Carruthers NI Bioorg Med Chem Lett; 2009 Feb; 19(3):903-7. PubMed ID: 19119007 [TBL] [Abstract][Full Text] [Related]
14. Acidic elements in histamine H(3) receptor antagonists. Sander K; von Coburg Y; Camelin JC; Ligneau X; Rau O; Schubert-Zsilavecz M; Schwartz JC; Stark H Bioorg Med Chem Lett; 2010 Mar; 20(5):1581-4. PubMed ID: 20138762 [TBL] [Abstract][Full Text] [Related]
16. 2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists. Zaragoza F; Stephensen H; Peschke B; Rimvall K J Med Chem; 2005 Jan; 48(1):306-11. PubMed ID: 15634025 [TBL] [Abstract][Full Text] [Related]
17. Determination of the binding mode and interacting amino-acids for dibasic H3 receptor antagonists. Levoin N; Labeeuw O; Krief S; Calmels T; Poupardin-Olivier O; Berrebi-Bertrand I; Lecomte JM; Schwartz JC; Capet M Bioorg Med Chem; 2013 Aug; 21(15):4526-9. PubMed ID: 23787288 [TBL] [Abstract][Full Text] [Related]
18. Discovery of a new class of non-imidazole oxazoline-based histamine H(3) receptor (H(3)R) inverse agonists. Célanire S; Wijtmans M; Christophe B; Collart P; de Esch I; Dassesse D; Delaunoy C; Denonne F; Durieu V; Gelens E; Gillard M; Lallemand B; Lamberty Y; Lebon F; Nicolas JM; Quéré L; Snip E; Vanbellinghen A; Van Houtvin N; Verbois V; Timmerman H; Talaga P; Leurs R; Provins L ChemMedChem; 2009 Jul; 4(7):1063-8. PubMed ID: 19405064 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists. Ali SM; Tedford CE; Gregory R; Handley MK; Yates SL; Hirth WW; Phillips JG J Med Chem; 1999 Mar; 42(5):903-9. PubMed ID: 10072687 [TBL] [Abstract][Full Text] [Related]
20. Discovery of quinazolines as histamine H4 receptor inverse agonists using a scaffold hopping approach. Smits RA; de Esch IJ; Zuiderveld OP; Broeker J; Sansuk K; Guaita E; Coruzzi G; Adami M; Haaksma E; Leurs R J Med Chem; 2008 Dec; 51(24):7855-65. PubMed ID: 19053770 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]